CS231146B1 - A method of producing a subcellular parenteral agent against neonatal colienteritis and calf and pig colts - Google Patents

Abstract

The invention relates to a new method of isolating the pilus body antigen K 99 of the bacterium Bscherichia coli. The said isolated antigen K 99 serves either for the immunization of pregnant cows and, more recently, of pregnant sows, or as a supplement to other vaccines against intestinal inflammation and diarrhea. It is used in large-scale animal production, where it significantly contributes to the reduction of neonatal mortality.

Description

1 231 148

BACKGROUND OF THE INVENTION The present invention relates to a method of producing an effective subcellular parenteral agent against neonatal clientxtidium and coli-kinetics of pigs, administered to mothers $ weeks prior to porosomycin to muscle or subcutaneously.

Colienteritis and calf and cradle is a serious problem for breeding farms * It is caused by enteropathogenic bacteria, Escherichia coli, carrying the K 99 pilusantigene on the surface of the body, which allows their adherence to intestinal stenunoral calves and, most recently, pigs and the epicenteritis, which results in persistent diarrhea and the dying of the animals at ten days after the babbling · Her conquered is very demanding and hamper, rarely soothing. So far, the most effective way to eliminate it is by immunizing newborn calves and pigs with autochthonous oral vakeins containing dead Escherichia colx bacteria, with pilus amphigene £ 99, or immunizing the same cows and dusty sows prior to pareoteral vaccinations containing either dead E-bacteria. coli £ 99+, or isolated antigen £ 99 · Oral vaccine has viaoero disadvantages · Requires continual doping of the vaccine with new strains, administration of large doses of vaccine daily, which reduces the work of vovelkoch · Paranterial cellular or subcellular vaccine and immunizes body cow or porcine pig and Following the tension of the wheels, the antibodies and mothers are transferred to the new en-ca. Parenteral suhcellular vaccines to date have been produced by demanding multi-stage chemical isolations requiring expensive equipment and complicated post op *

The above mentioned drawbacks are substantially obviated by the production of a subcellular pereteral agent against neonatal colloideritis and calf and pig colts, according to which the K 99 Plasma antigen is separated from the body of Escherichia coli by homegenization and isolated by isoelectric autofocusing to such a concentration. that it exhibits a clear precipitation precipitation line! in the anti-antisense agar K 99 agar to 1: 128. The advantage of this method of producing K 99 antigen is its uniqueness, energy saving * elimination of permanent operation of the apparatus and the need for any chemicals because the separation occurs only in pyrogen-free sterile water. Example

Enteropathogenic bacterium Escherichia coli K 99 * nonscepilus antigen K 99 is resuspended at 4 ° C in cold sterile distilled water with a homogenizer of 5 to 10 min at 3,000 1 / day to provide normal production of said antigenic edate and non-supernatant bacteria. min 4 ° C. This results in the separation of the piles containing the K 99 antigen. Thereafter, the homogeneity is centrifuged at 70,000 ms @ 2 for 20 min and at a temperature of about 0 DEG C. The supernatant is adjusted to values of up to 800 .mu.l by adding sterile distilled water. further addition of K 99 antigen is added to 231 146

horizontal isoelectrofocusing high-capacity apparatus with mechanically stabilized deleate solutions · Unidirectional electrical current is applied to the aperture apparatus at a maximum of 3 VA and the solution focuses at 4 ° C while the current does not fall below 3 mA at a rupture of 000 V · Pile the K 99 antigen focuses on pB 9.5 to 10.8 automatically · From the pffi compartments, the fimbrial pilus antigen S 99 is collected in this range. Its pH is adjusted to 7 to 7.5 and the concentration is adjusted to show agar® precipitation clear precipiaenilin anti K 99 diluent up to 1 sec 128 dilution · After this concentration is reached, a suitable adjuvant is added to the antigen solution, e.g., oily, and administered paremally by injection of 2 to 3 b! subcutaneously or intramuscularly to mothers about 6 weeks before pcrodoma · This dose and time are sufficient to allow mothers to develop antibodies to the K 99 antigen and to congest the collagen into the newborn era. The thiantibodies prevent the bacterial B bacteria from adhering to the intestinal wall and thereby cause coli-ding and cervix.

Can you find the invention? wide practical use of animal size production ·

Claims (1)

OBJECT OF YYIÍLEIS 231 148 A process for the production of a pareuterial subcellular anti-urinary colitis and calf and calf cadaver, characterized in that both pilas asthma K 99 and the body surface of the Escheriehia ooli bacteria are separated by hemogenization and isolation is achieved by isoolectriocyte. the predetermination line in the agar diffusion to the &lt; RTI ID = 0.0 &gt; K 99 < / RTI &gt;